# SAVE-O2 AI randomized trial: autonomous oxygen titration kept acutely ill adults in the target range 85% of the time vs 63% under usual care (JAMA Internal Medicine, 2026)

> In a peer-reviewed, multicenter randomized trial of 300 acutely ill adults at 4 U.S. hospitals, patients whose supplemental oxygen was managed by an autonomous closed-loop system (the O2matic PRO100) spent 85% of their time in the normoxemic target range versus 63% under clinician-managed usual care, an adjusted 21-percentage-point difference (95% CI 18-25 pp; P < .001). This case file records the figures from the primary JAMA Internal Medicine article, corroborates them against independent press, and marks the ceiling: it is a single, unblinded trial of a process outcome, not yet independently replicated.

- Verification status: verified
- Case type: deployment
- Provider: O2matic PRO100 — closed-loop, trend-based, autonomous oxygen titration system
- Client: SAVE-O2 AI randomized clinical trial (University of Colorado Anschutz-led; 4 U.S. tertiary care hospitals), Healthcare / acute inpatient care (named)
- Sector: healthcare / US / ops
- Verified on: 2026-08-28
- Canonical URL: https://theinternetninja.com/stories/save-o2-ai-autonomous-oxygen-titration-jama-85pct-vs-63pct-normoxemia-2026/
- Source: The Internet Ninja (theinternetninja.com), independent verified-proof platform

## Outcomes

| Metric | Before | After |
| --- | --- | --- |
| Proportion of time in the normoxemic target range (SpO2 90-96%), autonomous vs usual care | 63% (usual care) | 85% (autonomous); adjusted difference 21 pp, 95% CI 18-25 pp, P < .001 |
| Proportion of time in hypoxemia (SpO2 < 88%), autonomous vs usual care | 3.6% (usual care) | 2% (autonomous); adjusted difference -1.3 pp, 95% CI -2 to -0.5 pp, P = .002 |
| Trial scale | n/a | 300 adults (152 autonomous / 148 usual care) at 4 U.S. hospitals |

## Verification method

Primary figures fetched verbatim from the JAMA Internal Medicine article (doi:10.1001/jamainternmed.2026.4023) on 2026-08-27 and corroborated firsthand against two genuinely independent outlets, Healio (pulmonology press) and HealthDay News (via Pulmonology Advisor), plus the first-party CU Anschutz institutional release. All report 85% vs 63% normoxemia and 2.0% vs 3.6% hypoxemia. Returned to the checker; the residual limit is that this is a single, unblinded, not-yet-replicated trial of a process outcome.

## Full case file

**Verification status: IN CHECKING — not publish-ready, not `pending`, not verified.**

## The problem

Supplemental oxygen is one of the most common interventions in hospital care, yet
clinicians cannot watch every patient's oxygen saturation continuously, so patients
drift out of the intended range into either too little oxygen (hypoxemia) or too
much (hyperoxemia). The question this case file tests is narrow and measurable:
when an autonomous closed-loop system manages the oxygen flow instead of the
bedside clinician, does the share of time a patient actually spends in the target
range rise on the independent public record, rather than in a device maker's
brochure ([source](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852401)).

## What was built

The intervention tested was the O2matic PRO100, which the trial describes as "a
closed-loop, trend-based, autonomous oxygen titration system"
([source](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852401)).
The CU Anschutz institutional release describes the same device as continuously
monitoring oxygen levels and adjusting oxygen flow in real time using pulse
oximetry without requiring clinician intervention between assessments
([source](https://news.cuanschutz.edu/news-stories/cu-anschutz-led-trial-finds-ai-system-improves-oxygen-delivery-in-hospital-patients)).
To test it, investigators ran the SAVE-O2 AI trial: "300 adults...randomized...152
in the autonomous oxygen titration group and 148 in the usual care group" at "4
tertiary care hospitals", enrolling from "May 6, 2024, to November 17, 2025"
([source](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852401)).
The trial was academic-led and independent of the device maker: "This effort was
sponsored by the US Department of War's Defense Health Agency Research and
Engineering Directorate, Combat Casualty Care Portfolio"
([source](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852401)).

## The outcome

On its primary endpoint the trial reported that "the mean (SE) proportion of time
spent in normoxemia (Spo2 90%-96%) was greater in the autonomous oxygen titration
group than in the usual care group (85% [1%] vs 63% [2%]; adjusted RD, 21
percentage points [pp]; 95% CI, 18-25 pp; P < .001)"
([source](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852401)).
The independent pulmonology outlet *Healio* reported the same result: patients
receiving autonomous versus manual oxygen titration "spent a significantly higher
proportion of time in normoxemia (mean, 85% vs. 63%; adjusted risk difference, 21
percentage points; 95% CI, 18-25 percentage points; P < .001)"
([source](https://www.healio.com/news/pulmonology/20260813/autonomous-vs-manual-oxygen-titration-yields-more-time-in-normoxemia)),
and a second independent outlet, HealthDay News (carried by *Pulmonology Advisor*),
reported the same figures firsthand: "the mean proportion of time spent in
normoxemia was greater in the autonomous oxygen titration group versus the usual
care group (85 versus 63 percent)"
([source](https://www.pulmonologyadvisor.com/news/autonomous-oxygen-titration-increases-proportion-of-time-in-normoxemia/)).
The CU Anschutz release carried the headline figures too, "85 percent of their time
in the target oxygen range compared with 63 percent in the standard care group"
([source](https://news.cuanschutz.edu/news-stories/cu-anschutz-led-trial-finds-ai-system-improves-oxygen-delivery-in-hospital-patients)),
though as the lead academic center it is first-party to the investigators, not an
independent voice.

The safety-relevant tail moved too. The trial reported that "the mean (SE)
proportion of time spent in hypoxemia (Spo2 <88%), the key secondary outcome, was
lower in the autonomous oxygen titration group than in the usual care group (2.0%
[0.2%] vs 3.6% [0.4%]; adjusted RD, -1.3 pp; 95% CI, -2.0 to -0.5 pp; P = .002)"
([source](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852401)),
a result *Healio* and HealthDay News (via *Pulmonology Advisor*) each reported
independently in the same terms, the latter as "the mean proportion of time spent
in hypoxemia was lower in the autonomous oxygen titration group versus the usual
care group ... 2.0 versus 3.6 percent"
([source](https://www.healio.com/news/pulmonology/20260813/autonomous-vs-manual-oxygen-titration-yields-more-time-in-normoxemia))
([source](https://www.pulmonologyadvisor.com/news/autonomous-oxygen-titration-increases-proportion-of-time-in-normoxemia/)).

**A note on source strength.** The figures are anchored in a Tier-1 peer-reviewed
artifact and reported firsthand by two independent outlets, *Healio* and HealthDay
News (via *Pulmonology Advisor*), so the corroboration is solid. The residual limit
is the study itself, not the sourcing: the effect comes from a single trial, and it
was "unblinded" (open-label), which is a real weakness for a subjective process
measure even in a peer-reviewed journal
([source](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852401)).
The primary outcome is a process measure, the share of time in a target SpO2 band,
not a hard patient outcome such as mortality or ventilator-free days, and the
independent outlets are reporting the same one study rather than re-measuring it
([source](https://www.pulmonologyadvisor.com/news/autonomous-oxygen-titration-increases-proportion-of-time-in-normoxemia/)).
The 21 pp effect is real in this trial and independently reported; it has not yet
been independently replicated by a second RCT.

## How this was verified

- **Method:** The primary JAMA Internal Medicine article, *Autonomous Oxygen
  Titration for Maintaining Normoxemia in Acutely Ill Adults: The SAVE-O2 AI
  Randomized Clinical Trial* (Douin DJ, Rice JD, Xiao M, et al.; published online
  August 3, 2026; doi:10.1001/jamainternmed.2026.4023), was fetched live and its
  primary and secondary endpoints quoted verbatim for the time-in-normoxemia and
  time-in-hypoxemia figures, the sample size, the sites, the enrollment dates, the
  device and the funder. The 85% vs 63% and 2.0% vs 3.6% figures were then
  corroborated against two genuinely independent outlets, *Healio* (pulmonology
  press) and HealthDay News (carried by *Pulmonology Advisor*), each reporting the
  figures firsthand, plus the CU Anschutz institutional release (first-party to the
  investigators, not counted as independent).
- **Date verified:** 2026-08-27.
- **Not claimed:** that autonomous titration reduced mortality, length of stay or
  any hard patient outcome (the primary endpoint is time in the target SpO2 range,
  a process measure); that the effect has been independently replicated (only the
  single SAVE-O2 AI trial exists as of the research date); or any blinding of the
  intervention (the trial was unblinded / open-label).

## Sources

1. JAMA Internal Medicine (Douin DJ, Rice JD, Xiao M, et al.) — "Autonomous Oxygen
   Titration for Maintaining Normoxemia in Acutely Ill Adults: The SAVE-O2 AI
   Randomized Clinical Trial" · 2026-08-03 ·
   https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852401
   (archived: http://web.archive.org/web/20260825133436/https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852401)
   — **Tier 1** (primary peer-reviewed randomized-trial artifact; academic-led,
   sponsored by the Defense Health Agency, independent of the device maker;
   doi:10.1001/jamainternmed.2026.4023).
2. Healio (pulmonology) — "Autonomous vs. manual oxygen titration yields more time
   in normoxemia" · 2026-08-13 ·
   https://www.healio.com/news/pulmonology/20260813/autonomous-vs-manual-oxygen-titration-yields-more-time-in-normoxemia
   (archived: https://web.archive.org/web/20260826225811/https://www.healio.com/news/pulmonology/20260813/autonomous-vs-manual-oxygen-titration-yields-more-time-in-normoxemia)
   — **Tier 2** (independent specialty press; corroborates the 85% vs 63% primary
   result and the hypoxemia secondary result verbatim).
3. University of Colorado Anschutz Medical Campus — "CU Anschutz-Led Trial Finds AI
   System Improves Oxygen Delivery in Hospital Patients" · 2026-08-03 ·
   https://news.cuanschutz.edu/news-stories/cu-anschutz-led-trial-finds-ai-system-improves-oxygen-delivery-in-hospital-patients
   (archived: http://web.archive.org/web/20260804002033/https://news.cuanschutz.edu/news-stories/cu-anschutz-led-trial-finds-ai-system-improves-oxygen-delivery-in-hospital-patients)
   — **Tier 2** (institutional release from the lead academic center; corroborates
   the headline figures and the device; first-party to the investigators, so it is
   not counted as independent of the study itself).
4. Pulmonology Advisor (HealthDay News) — "Autonomous Oxygen Titration Increases
   Proportion of Time in Normoxemia" · 2026-08-03 ·
   https://www.pulmonologyadvisor.com/news/autonomous-oxygen-titration-increases-proportion-of-time-in-normoxemia/
   (archived: http://web.archive.org/web/20260827023838/https://www.pulmonologyadvisor.com/news/autonomous-oxygen-titration-increases-proportion-of-time-in-normoxemia/)
   — **Tier 2** (independent HealthDay News wire report, distinct publisher from
   Healio; restates the 85% vs 63% and 2.0% vs 3.6% figures firsthand).
5. PubMed (National Library of Medicine) — record for the SAVE-O2 AI trial ·
   2026 · https://pubmed.ncbi.nlm.nih.gov/42546017/
   (archived: https://web.archive.org/web/20260826225845/https://pubmed.ncbi.nlm.nih.gov/42546017/)
   — **Tier 1** (indexing record confirming the citation, authors and journal).

## Related case files

- [Penda Health's AI Consult clinical copilot in Kenya](/stories/penda-health-openai-ai-consult-clinical-copilot-16pct-fewer-diagnostic-errors-kenya-2025/)
  — another clinical-AI outcome where a strong process/documentation effect sits
  next to a null on the harder patient outcome, the same tension between a
  process win and a patient-outcome win recorded here.
- [Boston Children's and OpenAI o3 for rare-disease reanalysis](/stories/boston-childrens-manton-openai-o3-deep-research-rare-disease-reanalysis-18-diagnoses-376-cases-nejm-ai-2026/)
  — the peer-reviewed clinical-benchmark counterpart, useful for contrasting a
  diagnostic-accuracy result with this real-time control-system result.
- [METR's 2025 randomized controlled trial of AI coding tools](/stories/metr-rct-ai-coding-tools-slow-experienced-open-source-developers-19pct-2025/)
  — the evidence-standard reference: an independent RCT is the bar this file is
  measured against, and the reason a single unreplicated trial caps below green.